|Title||Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Francavilla, R, Polimeno, L, Demichina, A, Maurogiovanni, G, Principi, B, Scaccianoce, G, Ierardi, E, Russo, F, Riezzo, G, Di Leo, A, Cavallo, L, Francavilla, A, Versalovic, J|
|Journal||J Clin Gastroenterol|
|Date Published||2014 May-Jun|
|Keywords||Adolescent, Adult, Aged, Anti-Bacterial Agents, Breath Tests, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Gastrins, Helicobacter Infections, Helicobacter pylori, Humans, Lactobacillus reuteri, Male, Middle Aged, Probiotics, Prospective Studies, Treatment Outcome, Young Adult|
GOALS: The goals of this study were to investigate the role of a new probiotic preparation (Lactobacillus reuteri DSM 17938 and L. reuteri ATCC PTA 6475) in Helicobacter pylori infection.
BACKGROUND: Specific probiotic strains play a role in H. pylori infection for their ability to decrease bacterial load and gastritis, prevent antibiotic-associated side effects, and increase the eradication rate.
STUDY: This is a prospective, double-blind, randomized, placebo-controlled study in a tertiary care setting. A total of 100 H. pylori-positive naive patients received either L. reuteri combination (2×10 Colony Forming Units) or placebo during a 3-phase study (pre-eradication, eradication, and follow-up). All underwent C urea breath test (C-UBT), blood assessments of gastrin-17 (G17), endoscopy, and the Gastrointestinal Symptom Rating Scale. Eradication was confirmed by C-UBT 8 weeks after the completion of therapy.
RESULTS: Fifty patients were allocated in each group. During pre-eradication period, C-UBT δ decreased by 13% in L. reuteri combination as compared with a 4% increase in placebo (-13.2±34% vs. 4.3±27%; P
CONCLUSIONS: L. reuteri combination alone is able to exert an inhibitory effect on H. pylori growth, and when administered with eradication therapy, it determines a significant reduction in antibiotic-associated side effects. Moreover, L. reuteri combination was able to decrease serum G17 levels and to (not significantly) increase the H. pylori-eradication rate.
|Alternate Journal||J. Clin. Gastroenterol.|